N/A
Completed N=138
Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)
Source: ClinicalTrials.gov NCT00749684 ↗Enrolled (actual)
138
Serious AEs
8.0%
Results posted
Mar 2011
Primary outcomePrimary: Number of Participants With Disease Recurrence — 52 participants
Summary
The aim of this observational study is to document the efficacy and tolerability of high-dose interferon therapy in adult participants with malignant melanoma at high risk of relapse and to compare them with the survival times and relapse rates in previous studies (historical control).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Disease Recurrence |
52 | — |
| PRIMARY Relapse Free Survival Time |
54.1 | — |
Eligibility Criteria
Inclusion Criteria
- Male and female participants
- Age 18-70 years
- Malignant melanoma stage II or III (>/= 1.5 mm tumor thickness, no distant metastases or Malignant melanoma with lymph node metastases or Lymph node metastases with unknown primary tumor
- An excision border of at least 2 cm around the primary tumor
- Therapy must start within 12 weeks after surgery of the tumor/of the lymph node metastases
- ECOG status 0-1 (= Karnofsky Index >/= 80)
- Laboratory parameters
- Hematocrit >= 33%
- Leukocytes >= 3000/μl
- Thrombocytes >= 100000/μl
- Alanine aminotransferase(ALT) 5 years, or the tumor is a cervical carcinoma in situ, a basal cell carcinoma or cutaneous squamous cell carcinoma)
- Participants on corticosteroid treatment or treatment with an immunomodulating substance
- Preexisting psychiatric illness, particularly serious depression
- Prior adjuvant radio-, chemo-, or immuno-therapy
- Treatment with an investigational drug within the prior 30 days
- Participant history that includes cardiac arrhythmia, cardiac insufficiency requiring treatment, or anthracycline administration
- Myocardial infarction within the prior year
- An unstable medical condition (apart from the indication) that in the judgment of the investigating physician excludes the participants from the study
- Psoriasis (a relative exclusion criterion, since interferon can aggravate psoriasis; decision to be based on risk/benefit analysis)
Data sourced from ClinicalTrials.gov (NCT00749684). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.